
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a promising biotechnology company with a strong focus on developing transformative therapeutics for the treatment of retinal diseases. Their proprietary Antibody Biopolymer Conjugate (ABC) platform has shown positive results in various studies for different investigational medicines, including tarcocimab tedromer, KSI-501, and KSI-101. These three potential therapies hold high potential to address unmet medical needs and have shown promising results in clinical trials. The recent positive data from the Phase 3 GLOW2 study for Zenkuda in patients with non-proliferative diabetic retinopathy (NPDR) is a significant milestone for the company and has boosted our confidence in the potential of their ABC platform. The company's pipeline also includes other promising investigational medicines with upcoming pivotal data readouts that could serve as important catalysts for the stock. Furthermore, Kodiak Sciences has a strong financial position, with projected operational runway into 2027, reducing any financing risks for the company. The only potential risks to our positive outlook are if the developmental candidates fail to achieve peak commercial revenue estimates or if the company fails to secure capital resources.
Bears say
Kodiak Sciences is highly dependent on the success of its investigational medicines, particularly tarcocimab tedromer (Zenkuda or tarcocimab), which has not consistently shown efficacy in the clinic. There are also potential risks in the manufacturing of multi-component molecules, and the company may struggle to build a global sales and marketing infrastructure for commercialization without significant cash burn. While the success of the ABC platform is supported by positive results from the GLOW2 study, there are still uncertainties surrounding its efficacy and longer-term data for safety, making the outlook for Kodiak Sciences' stock negative.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares